Clinical Trials Logo

Clinical Trial Summary

This study aimed to clarify the relationship between blood glucose control and the FAI based pericoronary inflammation in low-risk ACS patients with or without diabetes. The results of this study are expected to provide evidence that quantitative assessment of pericoronary FAI helps monitor the local inflammatory activation in diabetic patients with poor glycemic control, therefore, pericoronary FAI evaluation, as a noninvasive imaging biomarker, plays an important role in early detecting coronary atherosclerosis risk in diabetes and allow timely providing appropriate risk reduction strategies in patients at high risk for future cardiovascular events.


Clinical Trial Description

Coronary inflammation has been shown to be a cause of the significantly increased risk of cardiovascular disease (CVD) in diabetic patients. This study aimed to investigate the relationship between coronary local inflammation detected by pericoronary fat attenuation index (FAI) and different blood glucose control levels in low-risk acute coronary syndrome (ACS) patients with or without diabetes.A total of 309 patients with low-risk ACS were included in the analysis. Patients were classified into three groups: non-diabetes, well-regulated diabetes and poorly regulated diabetes, depend on the presence or absence of diabetes and the glycemic control evaluated based on a target HbA1c value of 7%. Pericoronary FAI around the proximal of left anterior descending artery (LAD), left circumflex artery (LCX), and right coronary artery (RCA) were evaluated by CCTA, while systemic inflammatory variables and other biochemical indicators were detected by flow cytometry. The results of this study are expected to provide evidence that quantitative assessment of pericoronary FAI helps monitor the local inflammatory activation in diabetic patients with poor glycemic control, therefore, pericoronary FAI evaluation, as a noninvasive imaging biomarker, plays an important role in early detecting coronary atherosclerosis risk in diabetes and allow timely providing appropriate risk reduction strategies in patients at high risk for future cardiovascular events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05590858
Study type Observational
Source RenJi Hospital
Contact
Status Completed
Phase
Start date January 1, 2019
Completion date October 1, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT04149483 - Statin Treatment for UnruptureD Intracranial anEurysms Study Phase 2
Recruiting NCT05860400 - Efficacy and Safety of Comprehensive Treatment in Patients With IR-CAD: a Self-controlled Cohort Study
Not yet recruiting NCT05959759 - Dimethyl Fumarate Treatment for Intracranial Unruptured Aneurysms. Phase 4
Recruiting NCT04943783 - Atorvastatin in the TREATment of Intracranial Unruptured VertebroBasilar Dissecting Aneurysms N/A
Not yet recruiting NCT06007248 - Disease Characteristics of IR-CAD: a Case-control Study